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Investigation of 1P-LSD as a Novel Drug Therapy for 
Autism Spectrum Disorders
What is the overall efficacy of microdosing
1P-LSD in mitigating the symptoms of ASD?
What is the maximum 
drug dosage that will not 
induce a hallucinogenic 
effect?
How does 1P-LSD 
influence overexcitation of 
NMDA receptors?
Our results should provide insights into molecular 
mechanisms through which 1P-LSD improves brain 
connectivity. This information could be leveraged to 
mitigate some of the pathology that results in the 
symptoms associated with ASD. We focused on biological 
tests, but future research could focus on behavioral tests, 
such as the anxiolytic (elevated zero maze) test and the 
partition test. Our research focused on biomarkers 
surrounding the 5HT1A and NMDA receptors; future 
research could focus on alternative biomarkers and 
pathways for 1P-LSD. Our research focused on 1P-LSD as 
a novel serotonin agonist; future research could focus 
on LSD itself or other novel serotonin agonists. Future 
research could also focus on the application of our 
results from a mouse model to a human model.
Autism spectrum disorders (ASD) are defined by repetitive 
behaviors or impaired social communication. ASD 
encompasses a series of neurodevelopmental disorders that 
have various physiological manifestations (Goines & 
Ashwood, 2013). Due to the heterogeneity of ASD, the true 
mechanisms leading to the development of ASD and its 
symptoms remain unclear and require more research 
(Rossignol & Frye, 2012; Watts, 2008).
The 1p-LSD will be purified and dried out under inert gas. The resulting powder will be reconstituted in a vehicle 
composing of pure ethanol, emulphor, and physiological saline in a 1:1:18 ratio. Mass of 1P-LSD to be dissolved in 
vehicle and concentration of 1P-LSD for each dosage group. Dosage group 4 will be the same concentration as the 
reconstituted stock solution that will be securely stored in the Principal Investigator’s laboratory. The stock will be 
diluted to obtain the concentrations for lower dosage groups. Calculations were done using an average 25 g mice and a 
0.2 mL injection volume per mouse.
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Determine the maximum dose of 1P-LSD to not exhibit 
hallucinogenic response through behavioral observations
• Composed of 4 cohorts of differential dosages on 
control mice
• Observing head twitch response as a hallucinogenic 
indicator
Phase 2: 
Measure effect of 1P-LSD on NMDA receptor excitotoxicity
•Composed of 3 cohorts for positive control, negative 
control, and experimental mutant mice
•Elucidate NR2B receptor subunit activation and 
glutamate levels in the brain
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In Phase 1 of our experiment, we expect to determine the 
dosage levels that will be used in Phase 2. We expect to 
see NR2B receptor subunit levels decrease compared to 
the control as well as glutamate levels decrease 
compared to the control throughout Phase 2 of our 
experiment.
There are various disorders that contribute to the symptoms 
associated with ASD. Hyposerotonemia in the brain and its 
proposed role in creating dysfunctional NMDA receptor 
activity is one such disorder. The purpose of this project is to 
test whether 1-propionyl-lysergic acid diethylamide (1P-
LSD), an analogue of lysergic acid diethylamide (LSD) and 
serotonin agonist, has the potential to treat symptoms of 
ASD.
We also expect to see a decrease in compounds 
associated with cytotoxicity pathways, as well as 
a general increase in metabolites associated with 
serotonin signaling. Broadly, we expect our measured 
endpoints for the mutant mice post-treatment to 
approach those of the control mice before treatment.
Specifically we expect to see:
1P-LSD Dosing Scheme
Planned Analyses
Dosage group Mass of 1P-LSD (µg) /200 µL Concentration (µg/mL)
Dosage group 1: 0 µg 1P-LSD per kg of 
body weight
0 µg 0 µg/mL
Dosage group 2: 50 µg 1P-LSD per kg 
of body weight
1.25 µg 6.25 µg/mL
Dosage group 3: 100 µg 1P-LSD per kg 
of body weight
2.5 µg 12.5 µg/mL
Dosage group 4 (reconstituted stock): 
150 µg 1P-LSD per kg of body weight
3.75 µg 18.75 µg/mL
Decreased expression of 
NR2B receptor subunits in 
the brain post-treatment. This 
will be measured using 
western blotting 
and immunohistochemistry.
Decreased expression of 
glutamate in the brain 
post-treatment. This 
will be measured using gas 
chromatography-mass 
spectrometry.
Introduction
Future Research Goals
